Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tanvex Biopharma (6541) Stock Price & Analysis

6541 Stock Chart & Stats

NT$27.85NT$0.95(3.53%)
At close: 12:30 AM EST
TWD 30TWD 35Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
TWD 24.30 - TWD 28.35
52-Week Range
TWD 24.30 - TWD 65.50
Previous Close
TWD 26.90
Volume
N/A
Average Volume (3M)
434.00K
Market Cap
TWD 7.39B
Enterprise Value
TWD 12.13B
Total Cash (Recent Filing)
TWD 592.56M
Total Debt (Recent Filing)
TWD 2.08B
Price to Earnings (P/E)
―
Beta
0.38
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Sharp revenue growth indicates stronger commercial activity and potential progress in developing or accessing target markets. If sustained, expanding sales can improve operating leverage, support reinvestment in biologic programs, and strengthen Tanvex’s competitive position over the next several quarters.

Improved Leverage

The substantial reduction in debt-to-equity improves the company’s capital structure relative to prior years and may reduce balance-sheet pressure. Greater equity and asset levels also provide a stronger base for pursuing development and commercialization, even though losses remain significant.

Biosimilar Platform

A biosimilar-focused business targets biologic therapies where more affordable alternatives can address broad treatment demand. This model offers a structural opportunity to build products around established biologic markets while combining biopharma research, clinical development, manufacturing preparation, and market access.

Bears Say

Persistent Losses

Persistent operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. Negative EBIT and EBITDA limit internal funding capacity, weaken resilience, and indicate that Tanvex still needs meaningful improvement in scale, pricing, costs, or product mix.

Negative Cash Generation

Continued operating and free-cash-flow deficits mean the company is consuming substantial cash while developing and commercializing its business. This reduces financial flexibility, limits self-funded growth, and leaves future execution more exposed until operations move toward consistent cash generation.

Funding Dependence

Although leverage improved, ongoing operating deficits mean the company cannot yet rely on internally generated resources to support its plans. Continued funding dependence can constrain capital allocation, increase execution pressure, and make the path from development activity to durable profitability more difficult.

6541 FAQ

What was Tanvex Biopharma’s price range in the past 12 months?
Tanvex Biopharma lowest stock price was TWD 24.30 and its highest was TWD 65.50 in the past 12 months.
What is Tanvex Biopharma’s market cap?
Tanvex Biopharma’s market cap is TWD 7.39B.
When is Tanvex Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tanvex Biopharma’s earnings last quarter?
Tanvex Biopharma released its earnings results on Aug 12, 2026. The company reported -TWD 1.444 earnings per share for the quarter, beating the consensus estimate of -TWD 1.66 by TWD 0.216.
Is Tanvex Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Tanvex Biopharma pay dividends?
Tanvex Biopharma does not currently pay dividends.
What is Tanvex Biopharma’s EPS estimate?
Tanvex Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tanvex Biopharma have?
Tanvex Biopharma has 265,224,370 shares outstanding.
What happened to Tanvex Biopharma’s price movement after its last earnings report?
Tanvex Biopharma reported an EPS of -TWD 1.444 in its last earnings report, beating expectations of -TWD 1.66. Following the earnings report the stock price went down -0.765%.
Which hedge fund is a major shareholder of Tanvex Biopharma?
Currently, no hedge funds are holding shares in TW:6541
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology